Coprescription of clarithromycin or erythromycin with a statin in older adults increased the risk of hospitalization with rhabdomyolysis compared to azithromycin (RR 2.17; 95% CI 1.04-4.53).
Cohort (n=144,336)
Does coprescription of clarithromycin or erythromycin increase the risk of hospitalization with rhabdomyolysis in older continuous statin users compared to azithromycin?
Coprescribing CYP3A4-inhibiting macrolides (clarithromycin or erythromycin) with statins in older adults significantly increases the risk of statin toxicity, including rhabdomyolysis, acute kidney injury, and mortality.
Relative Risk: 2.17 (95% CI 1.04–4.53)
BACKGROUND: Clarithromycin and erythromycin, but not azithromycin, inhibit cytochrome P450 isoenzyme 3A4 (CYP3A4), and inhibition increases blood concentrations of statins that are metabolized by CYP3A4. OBJECTIVE: To measure the frequency of statin toxicity after coprescription of a statin with clarithromycin or erythromycin. DESIGN: Population-based cohort study. SETTING: Ontario, Canada, from 2003 to 2010. PATIENTS: Continuous statin users older than 65 years who were prescribed clarithromycin (n = 72,591) or erythromycin (n = 3267) compared with those prescribed azithromycin (n = 68,478). MEASUREMENTS: The primary outcome was hospitalization with rhabdomyolysis within 30 days of the antibiotic prescription. RESULTS: Atorvastatin was the most commonly prescribed statin (73%) followed by simvastatin and lovastatin. Compared with azithromycin, coprescription of a statin with clarithromycin or erythromycin was associated with a higher risk for hospitalization with rhabdomyolysis (absolute risk increase, 0.02% 95% CI, 0.01% to 0.03%; relative risk RR, 2.17 CI, 1.04 to 4.53) or with acute kidney injury (absolute risk increase, 1.26% CI, 0.58% to 1.95%; RR, 1.78 CI, 1.49 to 2.14) and for all-cause mortality (absolute risk increase, 0.25% CI, 0.17% to 0.33%; RR, 1.56 CI, 1.36 to 1.80). LIMITATIONS: Only older adults were included in the study. The absolute risk increase for rhabdomyolysis may be underestimated because the codes used to identify it were insensitive. CONCLUSION: In older adults, coprescription of clarithromycin or erythromycin with a statin that is metabolized by CYP3A4 increases the risk for statin toxicity. PRIMARY FUNDING SOURCE: Academic Medical Organization of Southwestern Ontario.
Patel et al. (Tue,) conducted a cohort in Continuous statin use (n=144,336). Clarithromycin or erythromycin vs. Azithromycin was evaluated on Hospitalization with rhabdomyolysis within 30 days of the antibiotic prescription (RR 2.17, 95% CI 1.04 to 4.53). Coprescription of clarithromycin or erythromycin with a statin in older adults increased the risk of hospitalization with rhabdomyolysis compared to azithromycin (RR 2.17; 95% CI 1.04-4.53).